Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Hemodynamics in T2DM
NCT03132181Phase 2Completed
- Sponsor
- RWTH Aachen University
- Start
- Apr 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by RWTH Aachen University. Started Apr 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03132181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132181.